Company intelligence / Profile preview
Corvus Pharmaceuticals
Burlingame, California, United Statescorvuspharma.com ↗
- Ownership
- Public · CRVS
- Development stage
- Phase 3
01
Overview
Soquelitinib has shown safety and efficacy signals in early cohorts of atopic dermatitis patients using rigorous endpoints; interim data from refractory T-cell lymphoma showed tumor responses; ciforadenant demonstrated activity alone or combined with atezolizumab in advanced renal cell cancer
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Small molecule inhibitorsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Angel PharmaceuticalsKidney Cancer Research Consortium
04
Financials
- Market cap
- $818.5M
- Total revenue
- $0
- Enterprise value
- $616.2M
Beyond the preview
Go deeper on Corvus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corvus Pharmaceuticals.